Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine

Figures

• 

  Fig. 1. Flowchart of patients enrolled in the trial. 167 subjects were screened for eligibility. 163 were enrolled and received the trial vaccination (safety analysis set, SAF). Five subjects were excluded from the full analysis set (FAS), and three subjects were excluded from the per protocol analysis (PP) due to protocol deviation. 162 subjects completed the trial and 1 discontinued. The analysis sets were 163 subjects for SAF, 158 for FAS, and 155 for PP.

• 

  Fig. 2. Reverse cumulative titre distribution for type 1 (A), 2 (B) and 3 (C) antibody titres following primary, booster and additional vaccination with IPV-Al (PP). Data from primary (VIPV-07) and booster (VIPV-07-E1) trials illustrate only subjects who participated in the present extension. Subjects received IPV-Al as primary, booster and additional vaccination, and had their blood collected at 4 years of age during visit 1 (pre-vaccination) and visit 2 (post-vaccination) of the present trial (VIPV-07-E2). Each figure includes six curves, a pre-booster (V1) solid line and a post-booster vaccination (V2) dotted line for each group. Analysis set: per protocol.